| Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. | |
| | |
MedLine Citation:
|
PMID: 22055282 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Current topical agents for field therapy of actinic keratoses have single mechanisms of action and must be applied for weeks. Ingenol mebutate gel, a novel drug for field therapy of actinic keratoses, appears to have a dual mechanism of action: (1) rapid lesion necrosis and (2) specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Because of the rapid destruction of actinic keratosis lesions after application of ingenol mebutate gel, treatment is necessary for only 2 or 3 days. The subsequent immune-mediated response targets any residual dysplastic epidermal cells. This dual mechanism of action should provide efficacy equivalent to that of current topical agents with a substantially shorter treatment period. |
| | |
Authors:
|
Robert H Rosen; Aditya K Gupta; Stephen K Tyring |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-4 |
Journal Detail:
|
Title: Journal of the American Academy of Dermatology Volume: - ISSN: 1097-6787 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-7 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7907132 Medline TA: J Am Acad Dermatol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. |
Affiliation:
|
Southern Suburbs Dermatology, Sydney, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Internet-delivered or mailed self-help treatment for insomnia? A randomized waiting-list controlled ...
Next Document: Recommendations and current practices for the reconstitution and storage of botulinum toxin type A.